Clalit collaborates with leading universities, global pharma, startups, and government agencies to accelerate impactful innovation. Our massive patient population and big data makes makes us a uniquely powerful partner in shaping the future of medicine and patient care. We don’t just study what works: we help build it, test it, and bring it to patients.
Clalit partners with leading pharmaceutical and biotech companies to design, test, and validate therapies that improve lives at scale. With over 5 million patients, decades of integrated digital records, and a trusted clinical network, we offer an unparalleled environment for real-world evidence, observational studies, and clinical trials.
Our collaborations have helped assess vaccine efficacy, advance precision oncology, and accelerate access to groundbreaking treatments – bridging discovery and delivery like few institutions in the world.
Partnering with Pfizer – Clalit’s data and research arm powered the worldwide adoption and record breaking roll-out time for the Covid Vaccine in 2020-2021.
Clalit partners with top academic institutions worldwide to push the boundaries of medical research and public health. Each year, our researchers co-author hundreds of peer-reviewed publications, lead dozens of joint research initiatives, and contribute to multi-disciplinary collaborations spanning fields like AI, chronic disease, and health equity.
These partnerships enable fellowships, shared faculty roles, and real-world studies grounded in Clalit’s vast clinical and population data – turning ideas into breakthroughs and research into impact.
Clalit’s research and clinical expertise inform healthcare policy and system design in Israel and beyond. Our population-scale insights, pioneering digital tools, and outcomes-based studies have been cited by ministries of health, the World Health Organization, and leading global health agencies.
From COVID-19 vaccine monitoring to value-based care delivery, Clalit collaborates with public institutions and health systems to translate data into better decisions – improving outcomes not only for our patients, but for populations worldwide.
Clalit actively partners with startups and digital health companies to co-develop, test, and scale technologies that improve care delivery and patient outcomes.
From AI-powered diagnostics to remote monitoring tools and digital therapeutics, we integrate innovation directly into our clinical workflows. With access to real-world clinical settings, population-scale data, and a streamlined evaluation framework, Clalit offers an ideal environment for early-stage technologies to prove their impact – fast.
As the U.S. partner of Clalit Health Services, the Israel Healthcare Foundation (IHF) plays a critical role in advancing healthcare across Israel.
For over a decade, IHF has engaged donors, foundations, and institutions worldwide to support Clalit’s mission: delivering excellent, accessible healthcare to a diverse and geographically dispersed population.
100% of every donation directly supports Israel’s healthcare needs. No overhead. No delays. Just impact.
For more than 20 years, Dr. Danielle Thau has been a licensed clinical psychologist in private practice in Stamford, CT. She specializes in treating patients and families who are experiencing chronic or acute medical crisis. She served as the Officer of Education and Israel Liaison of the Jewish Community Mental Health Initiative (JCMHI). Additionally, Dr. Thau is a member of the Board of Overseers at the Ferkauf Graduate School of Psychology, contributing her expertise to the advancement of psychological education and practice.
Director, Institutional Advancement
Rebekah Raz is a seasoned nonprofit development professional with over 25 years of experience cultivating major gifts and building strategic donor relationships within the Jewish community. As Senior Fundraiser for the Israel Healthcare Foundation, she connects high-capacity supporters to transformative healthcare projects across Israel. Her deep personal and professional ties to Israel fuel her commitment to strengthening its hospitals and frontline care.
Development Operations Manager
Sophia coordinates comprehensive development activities for the Israel Healthcare Foundation, serving as a key liaison between the U.S. team and our partners in Israel. She manages large-scale events, strategic donor stewardship, and oversees the complete lifecycle of major grant portfolios from initial application through final reporting. Additionally, Sophia leads research initiatives to identify and evaluate prospective donors and funding opportunities.
She received her Bachelor of Arts degree from Hampshire College, where she studied American Literature and Creative Writing.
Senior Resource Advisor
Margy-Ruth Davis is the founder and chair of Perry Davis Associates. Founded in 1986, Perry Davis Associates specializes in fundraising, board development and strategic planning. Ms. Davis formerly served as Executive Director of the Greater New York Conference on Soviet Jewry. In that capacity she organized the Solidarity Sunday marches; over 250,000 joined the marches each year. Ms. Davis was also the Associate Director of the Elaine Kaufman Cultural Center, where she established the Development Department; created an ongoing program of foundation support and corporate membership; and oversaw all aspects of board and donor relations. She currently heads the PDA strategic development program and supervises the communications and outreach strategy for a number of top clients.
Senior Resource Advisor
Perry Davis is the founder and president of Perry Davis Associates. Founded in 1986, Perry Davis Associates specializes in fundraising, board development and strategic planning. He has served in key positions in government, education, and the private sector. As the New York City Partnership’s Vice President for Economic Development, he directed the completion of the Partnership’s strategic plan and its new project selection process, and developed its first program-related budget of $8 million. Prior to joining the Partnership, Mr. Davis was the Director of Funded Programs for the New York City Board of Education, where he raised $350 million annually. Mr. Davis, who holds a doctorate in Government and Administration from Columbia University, has also served as an Assistant to the Mayor of New York City. He is the editor and a contributing author of a book on public-private partnerships published by the Academy of Political Science and has served as guest speaker at conferences sponsored by the White House, the International Downtown Association, and various corporations.
Steve is a member and Chair of the Public-Private Partnership Working Group and President of The United States Global Development Council. Steve is one of twelve Americans plus the Secretaries of State, Defense and Treasury to serve. Prior to this role, He previously served as CEO of the world largest international Jewish social service agency, the American Jewish Joint Distribution Committee.
John Richards, MD, MMM, CPE, began his healthcare career as a family and emergency medicine physician in the United States Army. He served as faculty at the Medical College of Georgia. Starting in 1980, as an early adopter of technology in health care, he has been a serial entrepreneur with over 35 startup companies. Dr. Richards pioneered concepts and products in many health-related fields: health promotion, disease prevention, mail-order pharmacy, physician office dispensing, alternate site infusion therapy, health care data acquisition and mining, and cost containment to name but a few. Dr. Richards has worked for over 4 decades to reformat population health & its delivery, consumer and provider access & expectations and medical systems to improve patient care outcomes & provider efficiencies
Dr. Benjamin Lebwohl received his MD from Columbia College of Physicians and Surgeons in 2003, and then completed his internship, residency, and chief residency in internal medicine at Columbia. He stayed at Columbia as a fellow in Digestive and Liver Disease, during which time he obtained a Masters in Patient Oriented Research from the Department of Biostatistics at the Mailman School of Public Health. He joined the faculty of the Celiac Disease Center at Columbia University in 2010.
Dr. Philip Lanzkowsky is a retired pediatric hematologist-oncologist. Dr. Lanzkowsky was instrumental in the development, planning and establishment of Schneider Children’s Hospital (now the Cohen Children’s Medical Center) and served as its Chief-of-Staff from the inception of the hospital in 1984 until 2008. He is currently a consultant to Cohen and to Schneider Children’s Medical Center in Israel.
Dr. Adam Goldstein is a Professor and Director of Departmental Advancement at the University of North Carolina (UNC) Department of Family Medicine. Dr. Goldstein is the Director of Tobacco Intervention Programs (Nicotine Dependence Program and Tobacco Prevention and Evaluation Program) at the UNC School of Medicine. Dr. Goldstein has taught internationally on leadership development, substance abuse, health policy, cancer and clinical medicine in Moldova, Ukraine, Armenia, Argentina, Chile, Haiti and Israel.
Dr. Feinstein is President and Chief Executive Officer of the Jewish Healthcare Foundation and its two supporting organizations, the Pittsburgh Regional Health Initiative and Health Careers Futures Dr. Feinstein serves on a number of nonprofit and for-profit boards, including the Board of Directors of NRHI, the Center for Innovation Advisory Committee at the National Board of Medical Examiners, the Board of Overseers at Brandeis University’s Heller School, and as co-chair of the Board of Directors for the Pennsylvania Health Funders Collaborative
Dr. Paul Appelbaum is the Elizabeth K. Dollard Professor of Psychiatry, Medicine and Law, and Director, Division of Law, Ethics and Psychiatry at Columbia. Dr. Appelbaum is Past President of the American Psychiatric Association, the American Academy of Psychiatry and the Law, and the Massachusetts Psychiatric Society, and has twice served as Chair of the Council on Psychiatry and Law and of the Committee on Judicial Action for the American Psychiatric Association (APA).
